Gossamer Bio, Inc.

NASDAQ:GOSS

Biotechnology

Healthcare
$11.43 +3.24%

+$0.01 today

Market cap
$69.91M
Beta
2.04
P/E (TTM)
-0.2
EPS (TTM)
-$0.77
52W Low $0.11High $3.87

Volume 0.24M

Average 19.76M

GOSS Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Gossamer Bio, Inc.NASDAQ: GOSS

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $232K fell 32.2% year over year, ahead of the -74.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.2% from the prior quarter. Over 3 fiscal years it compounded at -39.1% a year.

Context

  • Depreciation & amortization amounted to 2.1% of revenue in FY2025, down 1.6 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -32.2% holds above the trailing-twelve-month pace of -74.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$232K+2.2% QoQ
Last fiscal yearDec 2025
$1M-75.9% YoY
LTMMar 2026
$892K-74.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.2%——
1 year-75.9%——
3-year CAGR-39.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
1M USD
Year-over-year change
-75.9%
4-year CAGR
-33.6%

Depreciation & Amortization vs competitors

How GOSS compares with its peers on the latest reported figures

  • GOSS's LTM Mar 2026 depreciation & amortization of $892K is the 5th largest of the 9 companies compared; the peer median is $1.02M.
  • Its year-over-year change of -74.4% is the lowest of 8, against a peer median of +11.1%.
  • Depreciation & amortization amounts to 1.6% of revenue for GOSS, versus a peer median of 1.3%.
GOSS Competitors Peer median
Depreciation & Amortization for GOSS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RGNXREGENXBIO Inc.LTM Mar 2026$15.52M -3.0%+6.5%17.7%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$7.93M +15.5%+25.3%9.0%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$2.41M -1.0%+34.3%0.8%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$1.19M ——1.0%
GOSSGossamer Bio, Inc.LTM Mar 2026$892K -74.4%-39.1%1.6%
PRTAProthena Corporation plcLTM Mar 2026$856K +258.2%+6.4%1.5%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$555K -1.9%+13.3%0.8%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$481K +11.1%-33.4%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$112K +33.3%-34.1%—
Peer median (excluding GOSS) $1.02M+11.1%+6.5%1.3%

Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(234M)(229.38M)(179.82M)(56.53M)(170.37M)
Depreciation & Amortization5.17M4.43M4.39M4.15M1M
Deferred Income Tax00000
Stock-Based Compensation32.01M42.55M28.52M20.62M10.56M
Change in Working Capital774K(4.46M)(14.84M)39.46M(13.63M)
Accounts Receivables000(5.34M)(6.89M)
Inventory00000
Accounts Payables(4.43M)(1.81M)3.99M(1.66M)(2.75M)
Other Working Capital5.2M(2.65M)(18.83M)46.45M(3.99M)
Other Non-Cash Items7.17M(177K)2.6M(11.17M)1.18M
Operating Cash Flow(188.89M)(187.03M)(159.16M)(3.47M)(171.27M)
Capital Expenditures(1.62M)(475K)00(79K)
Acquisitions (Net)0(65K)000
Purchases of Investments(152.03M)(238.06M)(441.67M)(494.78M)(227.11M)
Sales of Investments36.23M237.5M330.7M523.8M383.54M
Other Investing Activities(75K)65K000
Investing Cash Flow(117.43M)(1.04M)(110.97M)29.02M156.36M
Debt Repayment0(5.81M)(11.61M)(12.58M)0
Common Stock Issued0119.95M201.32M464K6.43M
Common Stock Repurchased000629K0
Dividends Paid00000
Other Financing Activities3.33M2.95M444K00
Financing Cash Flow3.33M117.09M190.15M(11.49M)6.43M
Effect of Forex Changes(165K)(517K)110K(102K)141K
Net Change in Cash(303.15M)(71.49M)(79.86M)13.97M(8.34M)
Free Cash Flow(190.51M)(187.51M)(159.16M)(3.47M)(171.35M)

Gossamer Bio, Inc.

NASDAQ:GOSS

Intrinsic Alpha fair value

Locked

Current Price

$11.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.